The KN024 trial demonstrated that pembrolizumab monotherapy improved the overall response rate (ORR) and overall and progression-free survival (OS and PFS) compared to platinum doublet chemotherapy (PDC) in the first-line setting for advanced NSCLC patients with a high PDL1 expression (i.e., ≥50%) and no EGFR/ALK aberration [5]. This evidence concerns the gene ALK and non-small cell lung carcinoma.